Disclosed herein are stents for implantation within the body and methods for delivery and/or deployment. Certain embodiments disclosed herein may be used in procedures to treat May-Thurner syndrome and/or deep venous thrombosis and the resulting post-thrombotic syndrome.
May-Thurner syndrome, also known as iliac vein compression syndrome, is a condition in which compression of the common venous outflow tract of the left lower extremity may cause various adverse effects, including, but not limited to, discomfort, swelling, pain, and/or deep venous thrombosis (DVT) (commonly known as blood clots). May-Thurner syndrome occurs when the left common iliac vein is compressed by the overlying right common iliac artery, leading to stasis of blood, which may cause the formation of blood clots in some individuals. Other, less common, variations of May-Thurner syndrome have been described, such as compression of the right common iliac vein by the right common iliac artery.
While May-Thurner syndrome is thought to represent between two to five percent of lower-extremity venous disorders, it frequently goes unrecognized. Nevertheless, it is generally accepted that May-Thurner syndrome is about three times more common in women than it is in men and typically manifests itself between the age of twenty and forty. Patients exhibiting both hypercoagulability and left lower extremity thrombosis may be suffering from May-Thurner syndrome. To confirm that diagnosis, it may be necessary to rule out other causes for hypercoagulable state, for example by evaluating levels of antithrombin, protein C, protein S, factor V Leiden, and prothrombin G20210A.
By contrast to the right common iliac vein, which ascends almost vertically parallel to the inferior vena cava, the left common iliac vein takes a more transverse course. Along this course, it lies under the right common iliac artery, which may compress it against the lumbar spine. Iliac vein compression is a frequent anatomic variant—it is thought that as much as 50% luminal compression of the left iliac vein occurs in a quarter of healthy individuals. However, compression of the left common iliac vein becomes clinically significant only if such compression causes appreciable hemodynamic changes in venous flow or venous pressure, or if it leads to acute or chronic deep venous thrombosis, which will be discussed in more detail below. In addition to the other problems associated with compression, the vein may also develop intraluminal fibrous spurs from the effects of the chronic pulsatile compressive force from the overlying artery.
The narrowed, turbulent channel associated with May-Thurner syndrome may predispose the afflicted patient to thrombosis. And, the compromised blood flow often causes collateral blood vessels to form—most often horizontal transpelvis collaterals, connecting both internal iliac veins to create additional outflow possibilities through the right common iliac vein. Sometimes vertical collaterals are formed, most often paralumbar, which can cause neurological symptoms, like tingling and numbness.
Current best practices for the treatment and/or management of May-Thurner syndrome is proportional to the severity of the clinical presentation. Leg swelling and pain is best evaluated by vascular specialists, such as vascular surgeons, interventional cardiologists, and interventional radiologists, who both diagnose and treat arterial and venous diseases to ensure that the cause of the extremity pain is evaluated. Diagnosis of May-Thurner syndrome is generally confirmed one or more imaging modalities that may include magnetic resonance venography, and venogram, which, because the collapsed/flattened left common iliac may not be visible or noticed using conventional venography, are usually confirmed with intravascular ultrasound. To prevent prolonged swelling or pain as downstream consequences of the left common iliac hemostasis, blood flow out of the leg should be improved/increased. Early-stage or uncomplicated cases may be managed simply with compression stockings. Late-stage or severe May-Thurner syndrome may require thrombolysis if there is a recent onset of thrombosis, followed by angioplasty and stenting of the iliac vein after confirming the diagnosis with a venogram or an intravascular ultrasound. A stent may be used to support the area from further compression following angioplasty. However, currently available stenting options suffer from several complications—including severe foreshortenting, lack of flexibility (which can force the vessel to straighten excessively), vessel wear and eventual performation, increased load on and deformation of the stent causing early fatigue failure, and/or impedence of flow in the overlying left iliac artery potentially causing peripheral arterial disease. The compressed, narrowed outflow channel present in May-Thurner syndrome may cause stasis of the blood, which an important contributing factor to deep vein thrombosis.
Some patients suffering from May-Thurner syndrome may exhibit thrombosis while others may not. Nevertheless, those patients that do not experience thrombotic symptoms may still experience thrombosis at any time. If a patient has extensive thrombosis, pharmacologic and/or mechanical (i.e., pharmacomechanical) thrombectomy may be necessary. The hemostasis caused by May-Thurner syndrome has been positively linked to an increased incidence of deep vein thrombosis (“DVT”).
Deep vein thrombosis, or deep venous thrombosis, is the formation of a blood clot (thrombus) within a deep vein, predominantly in the legs. The right and left common iliac are common locations for deep vein thrombosis, but other locations of occurrence are common. Non-specific symptoms associated with the condition may include pain, swelling, redness, warmness, and engorged superficial veins. Pulmonary embolism, a potentially life-threatening complication of deep vein thrombosis, is caused by the detachment of a partial or complete thrombus that travels to the lungs. Post-thrombotic syndrome, another long-term complication associated with deep venous thrombosis, is a medical condition caused by a reduction in the return of venous blood to the heart and can include the symptoms of chronic leg pain, swelling, redness, and ulcers or sores.
Deep vein thrombosis formation typically begins inside the valves of the calf veins, where the blood is relatively oxygen deprived, which activates certain biochemical pathways. Several medical conditions increase the risk for deep vein thrombosis, including cancer, trauma, and antiphospholipid syndrome. Other risk factors include older age, surgery, immobilization (e.g., as experienced with bed rest, orthopedic casts, and sitting on long flights), combined oral contraceptives, pregnancy, the postnatal period, and genetic factors. Those genetic factors include deficiencies with antithrombin, protein C, and protein S, the mutation of Factor V Leiden, and the property of having a non-O blood type. The rate of new cases of deep vein thrombosis increases dramatically from childhood to old age; in adulthood, about 1 in 1000 adults develops the condition annually.
Common symptoms of deep vein thrombosis include pain or tenderness, swelling, warmth, redness or discoloration, and distention of surface veins, although about half of those with the condition have no symptoms. Signs and symptoms alone are not sufficiently sensitive or specific to make a diagnosis, but when considered in conjunction with known risk factors can help determine the likelihood of deep vein thrombosis. Deep vein thrombosis is frequently ruled out as a diagnosis after patient evaluation: the suspected symptoms are more often due to other, unrelated causes, such as cellulitis, Baker's cyst, musculoskeletal injury, or lymphedema. Other differential diagnoses include hematoma, tumors, venous or arterial aneurysms, and connective tissue disorders.
Anticoagulation, which prevents further coagulation but does not act directly on existing clots, is the standard treatment for deep vein thrombosis. Other, potentially adjunct, therapies/treatments may include compression stockings, selective movement and/or stretching, inferior vena cava filters, thrombolysis, and thrombectomy.
In any case, treatment of various venous maladies, including those described above, can be improved with stents. Improvements in stents for venous use are therefore desired.
Accordingly, the present invention is directed to an intravascular stent that obviates one or more of the problems due to limitations and disadvantages of the related art.
In an aspect of the present invention, a stent comprises an expandable first stent segment having a first stent segment compressed state and a first stent segment expanded state, the expandable first stent segment having a plurality of first rings connected to one another to form a series of said first rings, the first rings comprising a plurality of first ring struts, the first ring struts comprising shape memory alloy, the first ring struts connected such that each of the plurality of first rings comprises a sinusoidal pattern having first apices and first troughs, the first rings having a first radial force in the first stent segment expanded state; and an expandable second stent segment having a second stent segment compressed state and a second stent segment expanded state, the expandable second stent segment having a plurality of second rings connected to one another to form a series of said second rings, the second rings comprising a plurality of second ring struts, the second ring struts comprising shape memory alloy, the second ring struts connected such that each of the plurality of second rings comprises a sinusoidal pattern having second apices and second troughs, the second rings having a second radial force in the second stent segment expanded state; wherein the expandable first stent segment is contiguous with and adjacent to the expandable second stent segment; and wherein the first radial force is greater than the second radial force.
In another aspect of the present invention, a stent system comprises an expandable first stent segment having a first stent segment compressed state and a first stent segment expanded state, the expandable first stent segment having a plurality of first rings connected to one another to form a series of said first rings, the first rings comprising a plurality of first ring struts, the first ring struts comprising shape memory alloy, the first ring struts connected such that each of the plurality of first rings comprises a sinusoidal pattern having first apices and first troughs, the first rings having a first radial force in the first stent segment expanded state; an expandable second stent segment having a second stent segment compressed state and a second stent segment expanded state, the expandable second stent segment having a plurality of second rings connected to one another to form a series of said second rings, the second rings comprising a plurality of second ring struts, the second ring struts comprising shape memory alloy, the second ring struts connected such that each of the plurality of second rings comprises a sinusoidal pattern having second apices and second troughs, the second rings having a second radial force in the second stent segment expanded state; and an expandable third stent segment having a third stent segment compressed state and a third stent segment expanded state, wherein the third stent segment is between the expandable first stent segment and the expandable second stent segment and having a plurality of third rings connected to one another to form a series of said third rings, the third rings comprising a plurality of third ring struts, the third ring struts comprising shape memory alloy, the third ring struts connected such that each of the plurality of third rings comprises a sinusoidal pattern having third apices and third troughs, the third rings having a third radial force; wherein the expandable first stent segment is contiguous with and adjacent to the expandable third stent segment and the expandable third stent segment is continuous with and adjacent to the expandable second stent segment; and wherein the first radial force is greater than the second radial force, the third radial force is less than the first radial force and greater than the second radial force; and an additional stent having an end region configured to overlap a portion of the expandable second stent segment in vivo.
Further embodiments, features, and advantages of the intravascular stent, as well as the structure and operation of the various embodiments of the intravascular stent, are described in detail below with reference to the accompanying drawings.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.
The accompanying figures, which are incorporated herein and form part of the specification, illustrate an intravascular stent. Together with the description, the figures further serve to explain the principles of the intravascular stent described herein and thereby enable a person skilled in the pertinent art to make and use the intravascular stent.
Accurate placement is ideal in all medical interventions, but it is vital in areas where the end that is first deployed is critical. Such areas include at vessel bifurcations and branch vessels, so that the implant does not enter or interfere with the portion of the vessel that does not require treatment. Such a bifurcation is present at the inferior vena cava where it branches into right and left iliac veins, as described in more detail below.
May-Thurner syndrome, or iliac vein compression syndrome, occurs in the peripheral venous system when the iliac artery compresses the iliac vein against the spine as shown in
As shown, the strong right common iliac artery has compressed the iliac vein causing it to become narrowed. This is one possible, if not a classic, manifestation of May-Thurner syndrome. Over time, such narrowing may cause vascular scarring which can result in intraluminal changes that could precipitate iliofemoral venous outflow obstruction and/or deep vein thrombosis. As discussed above, venous insufficiency (i.e., a condition in which the flow of blood through the veins is impaired) can ultimately lead to various deleterious pathologies including, but not limited to, pain, swelling, edema, skin changes, and ulcerations. Venous insufficiency is typically brought on by venous hypertension that develops as a result of persistent venous obstruction and incompetent (or subcompetent) venous valves. Current treatments for venous outflow obstruction include anticoagulation, thrombolysis, balloon angioplasty and stenting.
Generally, disclosed herein are stents that include circumferential rings of alternating interconnected struts connected by flexible connectors. The stent may have open or closed cells of various configuration formed by an expandable material. The final expanded implanted configuration can be achieved through mechanical expansion/actuation (e.g., balloon-expandable) or self-expansion (e.g., Nitinol). An exemplary embodiment of the stents described herein are self-expanding implants comprising super elastic or shape memory alloy materials, but the stent is not so limited and may be formed of balloon-expandable material. According to an aspect of the present disclosure, an expandable stent has varying magnitudes of radial force, crush resistance and flexibility at different locations along the length of the stent, while at the same time, the different locations have the same or similar diameter in an expanded configuration of the stent.
As illustrated in
Generally radial force refers to both or either Radial Resistive Force (RRF) and Chronic Outward Force (COF). As shown in
The reinforcement ring may be an area of greater stiffness/crush resistance at an end portion of the stent. “Greater stiffness” here means having a stiffness/crush resistance greater than a portion of the stent adjacent the reinforcement ring. The reinforcement ring having greater stiffness may provide good inflow into the stent and through the vessel having the implant therein. While described herein as a “reinforcement ring,” the area of greater stiffness may be provided by an additional structure overlying the stent end (e.g., a “ring”) or may instead be an area where the strut structure is actually stronger, e.g. because the material forming the area of greater stiffness is inherently stiffer, a tighter cell structure, thicker struts or the like. For example, the reinforcement ring may have a different stent geometry, e.g., different strut width or is simply a fully-connected ring.
An exemplary embodiment of the reinforcement ring is illustrated in
Returning to the stent structure, as illustrated in
The relatively high radial/crush force segment 14 is intended to be placed in a vessel in the region of the vessel prone to compression or crushing, such as pinching/crushing of the underlying left common iliac vein 1601 against the vertebra 1602 caused by May-Thurner syndrome, as illustrated in
The length of stent L0 also includes a highly flexible segment 18, which has relatively greater flexibility than the high radial/crush force 14 segment along the length of the highly flexible segment 18. In addition, according principles of the present disclosure, the highly flexible segment 18 has a length L2, a diameter D2 and radial force, crush resistance RF2 and flexibility F2, where RF2<RF1 and F2>F1, such that the highly flexible segment is more flexible than the high radial/crush force segment 14. According to principles described herein, the highly flexible segment may be designed to withstand long term durability (fatigue) testing with a flexion range of 0-140 degrees. A radial resistive force RF2 of the highly flexible segment 18 may be in the range of 0.50 to 0.70 N/mm, for example.
The length of stent 10 may also include a transition segment 22 between the high radial/crush force segment 14 and the highly flexible segment 18, where the transition segment 22 has a length L3, a diameter D3 and radial force or radial resistive force (crush resistance) RF3 and flexibility F3, where RF1>RF3>RF2 and F1 and F2>F3>F1. The radial force or radial resistive force (crush resistance) RF3 and flexibility F3 of the transition segment 22 may vary over the length L3 of the transition segment 22 or may be constant along the length L3 of the transition segment 22.
Each of the high radial/crush force segment 14, transition segment 22 and highly flexible segment 18 has a different radial force, crush resistance and flexibility, which may be provided by different ring structures in each segment of the stent 10. As can be observed in
In the illustrated embodiment of
It is contemplated that the length L2 of the highly flexible segment 18 will be greater than the length L1 of the high radial/crush force segment which will be greater than the length L3 of the transition segment.
An exemplary embodiment structure of a stent 110 according to principles of the present disclosure is shown in
It should be noted that terms such as perpendicular, thickness, same, similar, and other dimensional and geometric terms should not be regarded as strict or perfect in their application. Instead, geometric and other dimensional reference terms should be interpreted based on their correspondence to accepted manufacturing tolerances and functional needs of the stent 110 on which they are employed. For example, the term “perpendicular” should be appreciated as affording a reasonable amount of angular variation due to manufacturing imperfections or the actual intentional curves cut or formed in the stent design 110. Also, any thickness, width or other dimension should be assessed based on tolerances and functional needs of the design rather than idealized measurements.
The thickness of the strut 128, on the other hand, is its depth in the radial direction which is generally perpendicular to the strut width measurement, as shown in
Each of the rings 112 is comprised of a plurality of ring struts 128 interconnected to form alternating peaks or apexes 120 and troughs 124. As shown in
The exemplary hybrid stent 110 illustrated in
As can be appreciated, foreshortening of the stent can be a particular problem for placement of a stent. In practice, stents with greater flexibility tend to foreshorten more. Accurate placement is ideal in all medical interventions, but it is of great interest in areas where the end that is first deployed is important. Such areas include at vessel bifurcations and branch vessels, so that the implant does not enter or interfere with the portion of the vessel that does not require treatment. Such a bifurcation is present at the inferior vena cava where it branches into right and left iliac veins, as described in more detail below.
As described herein, a stent according to principles described herein includes a high radial/crush force segment and a highly flexible segment. The high radial/crush force segment, with its stiffer structure, will have minimal foreshortening, and as a result, can allow for more accurate placement in the vessel into which it is implanted.
As illustrated in
To facilitate placement of the stent 10 at the junction of the left common iliac vein 1504 and the iliac vein 1503, the stent 10 may have a flared end adjacent the high radial force segment 14, as illustrated in
In an aspect of the present invention, a separate extension stent 50 may be included along with the stent 10. An embodiment of the separate extension stent 50 is illustrated in
An exemplary extension stent is illustrated in
The separate extension stent 50 is placed in the left iliac vein 1504 adjacent the highly flexible segment 18 of the hybrid stent 10 and may overlap the end of hybrid stent 10, as illustrated in
It should be noted that an extension stent as described herein may be used in combination with other stents as a “main stent”, besides the hybrid stent 10. In use, the extension stent can be used to allow for variation in placement.
In addition, the extension stent may include reinforcement rings where the reinforcement ring may be an area of greater stiffness/crush resistance at an end portion of the stent. “Greater stiffness” here means having a stiffness greater than a portion of the sent adjacent the reinforcement ring. The reinforcement ring having greater stiffness may provide good inflow into the stent and through the vessel having the implant therein. The reinforcement rings may make the extension stent easier to place with respect to the main stent, for example, by mitigating crushing of the ends as they are made to overlap. In addition, to facilitate placement, the ends of the extension stent and/or the stent to which it is to be placed adjacent can be coated with a polymer, such as urethane or PTFE. Also, the extension stent may include anchors, eyelets, radiopaque markers or other features to assist in placement of the extension stent. The extension stent may also be delivered with the main stent, or may be separately delivered to the vessel.
The extension stent may be delivered via an appropriate access site, (e.g. jugular, popliteal, etc.). The extension stent can be made to be “bidirectional”, such that it could be preloaded onto a delivery catheter without specific regard to the direction of the delivery (e.g., jugular, popliteal, etc.). E.g. the delivery can be made from above the treatment region or from below the treatment region. Such bidirectionality can be facilitated by the extensions stent geometry being symmetrical such that ends of the extension stent have the same geometry. The stent may be delivered by a coaxial delivery catheter. In another aspect of the present disclosure, a novel delivery device may include a cartridge that may be loaded onto a catheter and the hybrid sent also loaded on the catheter. The cartridge can be flipped by the operator for retrograde or anterograde. The stent may be preloaded onto the delivery catheter for the direction of the delivery (e.g., jugular, popliteal, etc.)
As can be appreciated, the actual stent ring geometry may vary from that disclosed herein, as long as the stent 10 includes a first section with a relatively higher radial force or crush resistance than a second section of the stent that has a relatively higher flexibility than the first section. It is also contemplated that the separate extension stent 50 have a flexibility similar to the highly flexible segment of the hybrid stent 10. Exemplary stent geometries for segments of the hybrid stent 10 and the extension stent 50 are taught in U.S. patent application Ser. Nos. 15/471,980 and 15/684,626, which are hereby incorporated by reference for all purposes as if fully set forth herein.
Each of the rings 212 is comprised of a plurality of ring struts 228 interconnected to form alternating peaks or apexes 240 and troughs 242. As shown in
Each of the connectors 232 itself is comprised a connector strut 234. In the present embodiment, the connector is a single connector strut 234, but the connector design is not necessarily limited to a single strut. As illustrated in
The connector struts 234—similar to the ring struts 228 of the exemplary embodiment—have a relatively constant width except where they connect to the rings 212. As with the ring struts 228 described above, the width of the connector struts 234 may enlarge somewhat as they merge into connections with the rings 212. As shown in
As illustrated in
Each of the rings 312 is comprised of a plurality of ring struts 328 interconnected to form alternating peaks or apexes 340 and troughs 342. As shown in
Each of the connectors 332 itself is comprised a connector strut 334. In the present embodiment, the connector 332 is a single connector strut 334, but the connector design is not necessarily limited to a single strut. As illustrated in
The connector struts 334—similar to the ring struts 328 of the exemplary embodiment—have a relatively constant width except where they connect to the rings 312. The width of the connector struts 334 may enlarge somewhat as they merge into connections with the rings 312.
The exemplary reinforcement ring segment 426 includes a plurality of rings 412 connected by a plurality of connectors 432. The rings 412 are arranged in a spaced relationship along a long axis of the reinforcement rings 426. The connectors 432 extend between adjacent pairs of rings 412. Each of the rings 412 is comprised of a plurality of interconnecting struts 428. The dimensions and orientation of these struts are designed to provide a relatively greater radial force such that the stent segment has a higher crush resistance than the adjacent transition segment or the highly flexible segment, (see
Each of the rings 412 is comprised of a plurality of ring struts 428 interconnected to form alternating peaks or apexes 440 and troughs 442. As shown in
Each of the connectors 432 itself may be comprised of a connector strut 434. In the present embodiment, the connector 432 is a single connector strut 434, but the connector design is not necessarily limited to a single strut. As illustrated in
The connector 432—similar to the ring struts 428 of the exemplary embodiment—have a relatively constant width except where they connect to the rings 412. The width of the connector struts 432 may enlarge somewhat as they merge into connections with the rings 412 or ring apices 440.
A hybrid stent 510 having separate segments of varying radial/crush force and flexibility according to principles described herein may benefit from a smooth transition between segments. In an aspect of the present hybrid stent, the high radial/crush force segment may include rings along the length of the stent that are designed to rotate with respect to one another, and the transition and flexible region, where the stent opens more uniformly, may have no rotation. Thus, an aspect may allow for smooth transition between two adjacent regions/segments of the stent to address crimp and deployment issues that may result from the twist of the last ring of the high radial/crush force segment creating a twist in the adjacent transition/flexible segment region.
It is noted that the struts of the rings and flexible connectors with structure, including areas of expanded or reduced width or thickness, to account for venous applications, may be used. As another example, it is noted that venous applications benefit from configurations that improve flexibility (due to the greater elasticity of venous applications) while maintaining enough stiffness to resist pressure on the venous structure in selected areas (such as for the May-Thurner syndrome).
Notably the stents herein are not necessarily limited to venous applications unless specifically required by the claims. The disclosed stents could be employed in arterial and biliary applications, for example. But, are particularly suited for the demands of relatively soft structures defining lumens that are subject to much greater bending, twisting, stretching and other contortions and loads than are general arterial lumens.
To deploy the implant, the implant may be radially compressed/crimped to a smaller diameter for loading onto/into a delivery catheter. The implant may be crimped over a balloon on the inner core of the delivery system which may be later inflated to expand the crimped implant to the desired diameter.
Implants such as those described above may advantageously provide an adaptive diameter and/or flexibility to conform the dynamic movement of peripheral veins in leg/pelvis thereby facilitating treatment of both iliac vein compression syndrome and ilio-femoral venous outflow obstructions.
It may be desirable to have a stent that will conform to the existing path of a vein instead of a straightening out of the vessel by the stent. It may also be desirable to have a high radial/crush stiffness of the stent to resist collapse of the stent under crushing load and to maximize the resultant diameter of the treated vessel at the location of the stent deployment. With most stent constructions there is a direct relationship between radial stiffness and axial stiffness.
Common commercially available balloon expandable stents experience a dramatic change in length as a balloon is used to expand the stent within the vessel. Common commercially available self-expanding stents experience a change in length less dramatic, but still substantial, which increases with increasing stent length. Change in length between the configuration within the delivery system and when deployed in the vessel causes difficulty in placing/landing the stent precisely at the target location. When the stent is delivered in its crimped configuration, then deployed or expanded, the shortening in length causes the stent target deployment location to have to offset from the target dwell location. The magnitude of this effect is not controllable or easily anticipated as it is dependent on the luminal cross-section along the length of the target dwell location (which is frequently and unexpectedly influenced by residual stenosis, irregular shape due to external objects, and/or forces, etc.). For target lesions leading up to the junction of the left and right iliac into the IVC, this causes difficulty in placing the stent to dwell completely within the iliac along its total length up to the junction to the inferior vena cava without crossing into the inferior vena cava. Placement of a high radial/crush force segment at the junction not only assists in addressing crush by May-Thurner Syndrome, but also may assist in reducing foreshortening from the target location.
Embodiments disclosed herein can be used for both balloon expandable and self-expanding stent designs. The stent designs can be used for all stent interventions, including coronary, peripheral, carotid, neuro, biliary and, especially, venous applications. Additionally, this could be beneficial for stent grafts, percutaneous valves, etc.
Currently available implants are typically loaded and retained onto a delivery system in a crimped configuration and then navigated and deployed in the desired anatomical location where they expand to the implanted configuration. The final implanted configuration can be achieved through mechanical expansion/actuation (e.g., balloon-expandable) or self-expansion (e.g., Nitinol). Self-expanding implants are manufactured from super elastic or shape memory alloy materials. Accurate and precise deployment of a self-expanding implant can be challenging due to a number of inherent design attributes associated with self-expanding implants. The implant may jump/advance from the distal end of the delivery system during deployment due to the stored elastic energy of the material. Additionally, the implant may foreshorten during deployment due to the change in the implant diameter from the crimped configuration to the expanded configuration. Finally, physiological and anatomical configurations, such a placement at or near bifurcations of body lumens, can affect accurate placement of implants. Once the implant is placed within the body lumen there is potential for uneven expansion or lack of circumferential implant apposition to the body lumen which can result in movement, migration or in certain severe cases implant embolization.
In some embodiments, a self-expanding implant designed with sufficient radial force or crush resistance to resist constant compression of the body lumen while providing optimal fatigue resistance, accurate placement, and in-vivo anchoring to prevent movement/migration is provided. Additionally, various methods for deployment and implantation for treating iliac vein compression syndrome and venous insufficiency disease are provided.
In some embodiments, the implant comprises a purposely designed venous implant intended to focally treat iliac vein compression (May-Thurner Syndrome). The implant may be relatively short in length (˜60 mm) and may be manufactured from self-expending Nitinol with integrated anchor features to aid in accurate placement and to mitigate migration following implantation. The implant and delivery system are designed for precise deployment and placement at the bifurcation of the inferior vena cava into the right and left common iliac veins.
As another feature, the stents disclosed herein can include anchor members, radiopaque markers, or eyelets, for example, set forth in pending U.S. patent application Ser. Nos. 15/471,980 and 15/684,626, which are hereby incorporated by reference for all purposes as if fully set forth herein.
Although this invention has been disclosed in the context of certain embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. In addition, while a number of variations of the invention have been shown and described in detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or sub-combinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the invention. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above but should be determined only by a fair reading of the claims that follow.
Similarly, this method of disclosure, is not to be interpreted as reflecting an intention that any claim require more features than are expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment. Thus, the claims following the Detailed Description are hereby expressly incorporated into this Detailed Description, with each claim standing on its own as a separate embodiment.
While various embodiments of the present invention have been described above, it should be understood that they have been presented by way of example only, and not limitation. It will be apparent to persons skilled in the relevant art that various changes in form and detail can be made therein without departing from the spirit and scope of the present invention. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments but should be defined only in accordance with the following claims and their equivalents.
This application is a continuation-in-part of U.S. application Ser. No. 16/397,085, filed Apr. 29, 2019, which is a division of U.S. application Ser. No. 15/712,704, filed Sep. 22, 2017, now U.S. Pat. No. 10,271,977, issued Apr. 30, 2019, which claims the benefit of U.S. Provisional Application No. 62/555,894, filed Sep. 8, 2017, all of which are hereby incorporated by reference in their entireties as if fully set forth herein. This application is also a continuation of U.S. application Ser. No. 16/288,744, filed Feb. 28, 2019, which is hereby incorporated by reference in its entirety as if fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
5064435 | Porter | Nov 1991 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5827321 | Roubin et al. | Oct 1998 | A |
5836966 | St. Germain | Nov 1998 | A |
5843120 | Israel et al. | Dec 1998 | A |
5843175 | Frantzen | Dec 1998 | A |
5868780 | Lashinski et al. | Feb 1999 | A |
5868782 | Frantzen | Feb 1999 | A |
5911754 | Kanesaka et al. | Jun 1999 | A |
5922005 | Richter et al. | Jul 1999 | A |
5938697 | Killion et al. | Aug 1999 | A |
5964798 | Imran | Oct 1999 | A |
5972018 | Israel et al. | Oct 1999 | A |
6027526 | Limon et al. | Feb 2000 | A |
6033433 | Ehr | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6059811 | Pinchasik et al. | May 2000 | A |
6068656 | Von Oepen | May 2000 | A |
6083259 | Frantzen | Jul 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6113627 | Jang | Sep 2000 | A |
6123721 | Jang | Sep 2000 | A |
6146403 | St. Germain | Nov 2000 | A |
6156052 | Richter et al. | Dec 2000 | A |
6179868 | Burpee et al. | Jan 2001 | B1 |
6183507 | Lashinski et al. | Feb 2001 | B1 |
6190403 | Fischell et al. | Feb 2001 | B1 |
6200334 | Jang | Mar 2001 | B1 |
6203569 | Wijay | Mar 2001 | B1 |
6235053 | Jang | May 2001 | B1 |
6241762 | Shanley | Jun 2001 | B1 |
6261319 | Kveen | Jul 2001 | B1 |
6287336 | Globerman et al. | Sep 2001 | B1 |
6299635 | Frantzen | Oct 2001 | B1 |
6309414 | Rolando et al. | Oct 2001 | B1 |
6325821 | Gaschino et al. | Dec 2001 | B1 |
6325825 | Kula et al. | Dec 2001 | B1 |
6402777 | Globerman et al. | Jun 2002 | B1 |
6423084 | St. Germain | Jul 2002 | B1 |
6428570 | Globerman et al. | Aug 2002 | B1 |
6443982 | Israel et al. | Sep 2002 | B1 |
6451049 | Vallana et al. | Sep 2002 | B2 |
6461380 | Cox | Oct 2002 | B1 |
6461381 | Israel et al. | Oct 2002 | B2 |
6464722 | Israel et al. | Oct 2002 | B2 |
6475236 | Roubin | Nov 2002 | B1 |
6478816 | Kveen et al. | Nov 2002 | B2 |
6485508 | McGuinness | Nov 2002 | B1 |
6485509 | Killion et al. | Dec 2002 | B2 |
6497723 | Starck et al. | Dec 2002 | B1 |
6540775 | Fischell et al. | Apr 2003 | B1 |
6635084 | Israel et al. | Oct 2003 | B2 |
6638300 | Frantzen | Oct 2003 | B1 |
6641609 | Globerman | Nov 2003 | B2 |
6660019 | Richter et al. | Dec 2003 | B1 |
6679911 | Burgermeister | Jan 2004 | B2 |
6682554 | Oepen et al. | Jan 2004 | B2 |
6692522 | Richter | Feb 2004 | B1 |
6699281 | Vallana et al. | Mar 2004 | B2 |
6706061 | Fischell et al. | Mar 2004 | B1 |
6709453 | Pinchasik et al. | Mar 2004 | B2 |
6730116 | Wolinsky et al. | May 2004 | B1 |
6746479 | Ehr et al. | Jun 2004 | B2 |
6761731 | Majercak | Jul 2004 | B2 |
6764506 | Roubin et al. | Jul 2004 | B2 |
6786922 | Schaeffer | Sep 2004 | B2 |
6790227 | Burgermeister | Sep 2004 | B2 |
6818015 | Hankh et al. | Nov 2004 | B2 |
6923829 | Boyle et al. | Aug 2005 | B2 |
6939373 | Gomez et al. | Sep 2005 | B2 |
6945993 | Kveen et al. | Sep 2005 | B2 |
7004968 | Lootz et al. | Feb 2006 | B2 |
7029493 | Majercak et al. | Apr 2006 | B2 |
7037330 | Rivelli, Jr. et al. | May 2006 | B1 |
7060088 | Fischell et al. | Jun 2006 | B1 |
7060090 | Thornton | Jun 2006 | B2 |
7070614 | Neuss et al. | Jul 2006 | B1 |
7131993 | Gregorich | Nov 2006 | B2 |
7141062 | Pinchasik et al. | Nov 2006 | B1 |
7273494 | Rolando et al. | Sep 2007 | B2 |
7316710 | Cheng et al. | Jan 2008 | B1 |
7326243 | Kveen et al. | Feb 2008 | B2 |
7344563 | Vallana et al. | Mar 2008 | B2 |
7357813 | Burgermeister | Apr 2008 | B2 |
7402169 | Killion | Jul 2008 | B2 |
7485130 | St. Germain | Feb 2009 | B2 |
7527644 | Mangiardi et al. | May 2009 | B2 |
7621947 | Richter et al. | Nov 2009 | B2 |
7648526 | Sano et al. | Jan 2010 | B2 |
7686843 | Moore | Mar 2010 | B2 |
7731746 | Kveen et al. | Jun 2010 | B2 |
7806918 | Nissl et al. | Oct 2010 | B2 |
7862607 | McDermott et al. | Jan 2011 | B2 |
7896912 | Shanley | Mar 2011 | B2 |
8012196 | Smith et al. | Sep 2011 | B2 |
8016874 | Casey | Sep 2011 | B2 |
8034098 | Callas et al. | Oct 2011 | B1 |
8128679 | Casey | Mar 2012 | B2 |
8137396 | Busold et al. | Mar 2012 | B2 |
8206427 | Ryan et al. | Jun 2012 | B1 |
8211163 | Dakin et al. | Jul 2012 | B2 |
8221489 | Issenmann et al. | Jul 2012 | B2 |
8257424 | Orlowski | Sep 2012 | B2 |
8267991 | Scheerder et al. | Sep 2012 | B2 |
8317854 | Ryan et al. | Nov 2012 | B1 |
8317859 | Snow et al. | Nov 2012 | B2 |
8337544 | Osman et al. | Dec 2012 | B2 |
8348990 | Boyle et al. | Jan 2013 | B2 |
8470021 | Magnuson | Jun 2013 | B2 |
8524132 | Oepen et al. | Sep 2013 | B2 |
8562665 | Jang | Oct 2013 | B2 |
8647379 | McDermott et al. | Feb 2014 | B2 |
8652196 | Nissl | Feb 2014 | B2 |
8668731 | Kveen et al. | Mar 2014 | B2 |
8888837 | Obradovic et al. | Nov 2014 | B2 |
8974514 | Anukhin | Mar 2015 | B2 |
9066825 | Chanduszko | Jun 2015 | B2 |
9320627 | Casey | Apr 2016 | B2 |
9375810 | Mangiardi | Jun 2016 | B2 |
9408727 | Ainsworth et al. | Aug 2016 | B2 |
9498360 | Layman et al. | Nov 2016 | B2 |
9554927 | Bales, Jr. et al. | Jan 2017 | B2 |
9561123 | Bales, Jr. et al. | Feb 2017 | B2 |
9622850 | Bebb | Apr 2017 | B2 |
9649211 | Bonsignore et al. | May 2017 | B2 |
9655998 | Gemborys | May 2017 | B2 |
9668895 | Dreher | Jun 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9693860 | Sandstrom et al. | Jul 2017 | B2 |
9700448 | Snow et al. | Jul 2017 | B2 |
9707110 | McDermott et al. | Jul 2017 | B2 |
9724220 | Rasmussen | Aug 2017 | B2 |
9770348 | Wack | Sep 2017 | B2 |
9795496 | Armstrong et al. | Oct 2017 | B2 |
9839538 | Grewe et al. | Dec 2017 | B2 |
9839540 | Armstrong et al. | Dec 2017 | B2 |
10271977 | Longo et al. | Apr 2019 | B2 |
10512556 | Longo et al. | Dec 2019 | B2 |
10588764 | Longo et al. | Mar 2020 | B2 |
20010004705 | Killion et al. | Jun 2001 | A1 |
20010014822 | Milo | Aug 2001 | A1 |
20010047200 | White et al. | Nov 2001 | A1 |
20020013616 | Carter et al. | Jan 2002 | A1 |
20020042648 | Schaldach et al. | Apr 2002 | A1 |
20020052645 | Kugler | May 2002 | A1 |
20020058990 | Jang | May 2002 | A1 |
20020099406 | St. Germain | Jul 2002 | A1 |
20030009214 | Shanley | Jan 2003 | A1 |
20030014102 | Hong et al. | Jan 2003 | A1 |
20030074056 | Killion et al. | Apr 2003 | A1 |
20030100941 | Fischell et al. | May 2003 | A1 |
20030105513 | Moriuchi et al. | Jun 2003 | A1 |
20030105517 | White et al. | Jun 2003 | A1 |
20030135265 | Stinson | Jul 2003 | A1 |
20030144724 | Murray, III | Jul 2003 | A1 |
20040054398 | Cully et al. | Mar 2004 | A1 |
20040054400 | Granada | Mar 2004 | A1 |
20040102835 | Israel et al. | May 2004 | A1 |
20040102838 | Killion | May 2004 | A1 |
20040133265 | Duffy | Jul 2004 | A1 |
20040243216 | Gregorich | Dec 2004 | A1 |
20040254627 | Thompson et al. | Dec 2004 | A1 |
20040267350 | Roubin et al. | Dec 2004 | A1 |
20050004657 | Burgermeister | Jan 2005 | A1 |
20050021130 | Kveen | Jan 2005 | A1 |
20050060024 | Lee et al. | Mar 2005 | A1 |
20050080479 | Feng et al. | Apr 2005 | A1 |
20060025852 | Armstrong et al. | Feb 2006 | A1 |
20060129227 | Hengelmolen | Jun 2006 | A1 |
20060173531 | Richter | Aug 2006 | A1 |
20070010869 | Sano | Jan 2007 | A1 |
20070213806 | Roubin et al. | Sep 2007 | A1 |
20070213807 | Roubin et al. | Sep 2007 | A1 |
20070219613 | Kao et al. | Sep 2007 | A1 |
20070260300 | Gregorich et al. | Nov 2007 | A1 |
20080009938 | Huang et al. | Jan 2008 | A1 |
20080046072 | Laborde et al. | Feb 2008 | A1 |
20080051878 | Cheng et al. | Feb 2008 | A1 |
20080140181 | Reynolds et al. | Jun 2008 | A1 |
20080262593 | Ryan et al. | Oct 2008 | A1 |
20080288048 | Rolando et al. | Nov 2008 | A1 |
20090018641 | Binkert | Jan 2009 | A1 |
20090062899 | Dang et al. | Mar 2009 | A1 |
20090099652 | Granada | Apr 2009 | A1 |
20090264979 | Kao et al. | Oct 2009 | A1 |
20100004736 | Rolando et al. | Jan 2010 | A1 |
20100042202 | Ramzipoor et al. | Feb 2010 | A1 |
20100222864 | Rivelli, Jr. et al. | Sep 2010 | A1 |
20100241216 | Rolando et al. | Sep 2010 | A1 |
20100274346 | Chouinard et al. | Oct 2010 | A1 |
20100274348 | Schaffner et al. | Oct 2010 | A1 |
20110125251 | Cottone et al. | Feb 2011 | A1 |
20110106237 | Bonsignore | May 2011 | A1 |
20110230957 | Bonsignore et al. | Sep 2011 | A1 |
20110264186 | Berlung et al. | Oct 2011 | A1 |
20110301685 | Kao | Dec 2011 | A1 |
20120043703 | Von Oepen et al. | Feb 2012 | A1 |
20120046729 | Von Oepen et al. | Feb 2012 | A1 |
20120046730 | Von Oepen et al. | Feb 2012 | A1 |
20120046731 | Von Oepen et al. | Feb 2012 | A1 |
20120046733 | Von Oepen et al. | Feb 2012 | A1 |
20120046739 | Von Oepen et al. | Feb 2012 | A1 |
20120143312 | Brown | Jun 2012 | A1 |
20120277844 | Wu | Nov 2012 | A1 |
20120310327 | McHugo | Dec 2012 | A1 |
20130178928 | Vyas et al. | Jul 2013 | A1 |
20130289708 | Cox et al. | Oct 2013 | A1 |
20130304192 | Chanduszko | Nov 2013 | A1 |
20130325141 | Gill | Dec 2013 | A1 |
20140025157 | Abunassar | Jan 2014 | A1 |
20140277332 | Slazas et al. | Sep 2014 | A1 |
20140277365 | Gillespie | Sep 2014 | A1 |
20140277378 | Lane et al. | Sep 2014 | A1 |
20150105852 | Noffke et al. | Apr 2015 | A1 |
20150209167 | Mangiardi | Jul 2015 | A1 |
20150250580 | Besselink | Sep 2015 | A1 |
20150265437 | Fleury et al. | Sep 2015 | A1 |
20160113789 | Fleury et al. | Apr 2016 | A1 |
20160135970 | Schaeffer et al. | May 2016 | A1 |
20160235562 | Casey | Aug 2016 | A1 |
20160250052 | Kaspar | Sep 2016 | A1 |
20160287418 | Cheng et al. | Oct 2016 | A1 |
20170035548 | Bebb et al. | Feb 2017 | A1 |
20170071768 | Krieger et al. | Mar 2017 | A1 |
20170086994 | Bales et al. | Mar 2017 | A1 |
20170100267 | Bales et al. | Apr 2017 | A1 |
20170224878 | Gemborys | Aug 2017 | A1 |
20170265998 | Sandstrom et al. | Sep 2017 | A1 |
20170312104 | McDermott et al. | Nov 2017 | A1 |
20170312105 | McDermott et al. | Nov 2017 | A1 |
20170340464 | Kovach et al. | Nov 2017 | A1 |
20180055665 | Gorochow | Mar 2018 | A1 |
20180318113 | Sirhan et al. | Nov 2018 | A1 |
Number | Date | Country |
---|---|---|
104042376 | Sep 2014 | CN |
107773333 | Mar 2018 | CN |
0800801 | Oct 1997 | EP |
1059894 | Dec 2000 | EP |
3043754 | Jul 2016 | EP |
2007-500051 | Jan 2007 | JP |
2013528112 | Jul 2013 | JP |
2014138851 | Jul 2014 | JP |
2015038790 | Mar 2015 | WO |
2016046413 | Mar 2016 | WO |
2017042329 | Mar 2017 | WO |
2017050710 | Mar 2017 | WO |
Entry |
---|
International Search Report and Written Opinion dated Nov. 19, 2018, from International Application No. PCT/US2018/049656, 10 pages. |
International Search Report and Written Opinion dated Jun. 8, 2020, from International Application No. PCT/US2020/019791, 12 pages. |
Notice of Allowance issued for U.S. Appl. No. 16/799,233, dated Jan. 20, 2022. |
Office Action issued for U.S. Appl. No. 16/288,744, dated Jul. 22, 2021. |
Office Action issued for U.S. Appl. No. 16/799,233, dated Sep. 28, 2021. |
International Preliminary Report on Patentability dated Mar. 19, 2020, from International Application No. PCT/US2018/049656, 9 pages. |
Office Action issued in co-pending U.S. Appl. No. 16/288,744, dated Jun. 27, 2019. |
Office Action issued in co-pending U.S. Appl. No. 16/288,744, dated Jan. 10, 2020. |
Office Action issued for Japanese Application No. 2020-513897, dated Apr. 1, 2022. |
Extended European Search Report dated May 20, 2021 in EP Application No. 18854282. |
Office Action issued for Japanese Application No. 2020-513897, dated Nov. 9, 2022 (and English Translation). |
Office Action and Search Report issued for Chinese Application No. 201680058236.7, dated Oct. 8, 2022 (and English Translation). |
Number | Date | Country | |
---|---|---|---|
20200197200 A1 | Jun 2020 | US |
Number | Date | Country | |
---|---|---|---|
62555894 | Sep 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15712704 | Sep 2017 | US |
Child | 16397085 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16288744 | Feb 2019 | US |
Child | 16397085 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16397085 | Apr 2019 | US |
Child | 16802991 | US |